Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
March 10 2021 - 4:32PM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced that two abstracts on
AGEN1181, Agenus' Fc-enhanced next-generation anti-CTLA-4 antibody,
were accepted for presentation at the American Association for
Cancer Research (AACR) Annual Meeting from April 10 - 15, 2021.
In a Phase 1/2 clinical study, AGEN1181 has shown responses in
tumors previously unresponsive to immune therapies, including
ovarian cancer and MSS endometrial and colorectal cancers. The AACR
presentation will cover the most up to date data. AGEN1181 is
active even in patients with the low affinity FcγRIIIA allele, a
genetic polymorphism which makes them generally unresponsive to
first generation anti-CTLA-4. Further, AGEN1181 has demonstrated
the ability to deplete intratumoral Tregs. Tregs are
immunosuppressive T cells, and their depletion can allow for an
improved antitumor immune response. Importantly, AGEN1181 is active
without the neuroendocrine toxicities or hypophysitis observed with
first generation agents.
The data to be presented at AACR will showcase the optimal
performance of AGEN1181 in preclinical models and in clinical
trials. Preclinical data show that AGEN1181’s Fc enhancement allows
it to engage the immune system even in cases of patients with the
low affinity FcyRIIIA allele, which first-generation molecules do
not do. These data also show that across all observed populations,
AGEN1181 has increased efficacy over first-generation antibodies,
and that combinations with multiple agents including checkpoint
inhibitors such as anti-PD-1 and anti-TIGIT, iNKT-activating
therapy, and adoptive T cell therapy, could further increase that
efficacy.
In addition, clinical data to date provide evidence that these
observations are being borne out in patients. Responses have been
observed in patients with in the low-affinity FcyRIIIA allele.
Further, AGEN1181 is the first anti-CTLA-4 to show intratumoral
Treg depletion in the clinic.
AGEN1181 is currently advancing in a Phase 2 trial in colorectal
cancer alone and in combination with balstilimab, Agenus’ anti-PD-1
antibody. As of February 9, Agenus has reported 6 confirmed
objective clinical responses in its AGEN1181 Phase 1/2 trial and no
complement-mediated toxicities.
Presentation Details:
Abstract title: Fc-enhanced anti-CTLA-4 antibody,
AGEN1181: New mechanistic insights for potent antitumor immunity
and combination potential in treatment-resistant solid
tumorsPresenting author: Antoine Tanne, PhD
Abstract title: Characterization of the pharmacodynamic
activity of AGEN1181, an Fc-enhanced CTLA-4 antibody, alone and in
combination with the PD-1 antibody balstilimabPresenting
author: Irina Shapiro, PhD
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding clinical development plans and timelines, the
therapeutic potential of AGEN1181 alone and in combination with
other agents, as well as the anticipated presentation of updated
clinical and preclinical data. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024